C L Sampieri1, R A Orozco-Ortega2. 1. Instituto de Salud Pública, Universidad Veracruzana, Xalapa, Veracruz, México. 2. Facultad de Bioanálisis, Universidad Veracruzana, Xalapa, Veracruz, México.
Abstract
INTRODUCTION: Matrix metalloproteinases (MMPs) are a family of zinc-dependent proteinases involved in remodeling the extracellular matrix. Tissue inhibitors of metalloproteinases (TIMPs) are a family of four proteins that act to limit the degradative actions of MMPs. Chronic kidney disease (CKD) and acute kidney injury (AKI) are public health problems worldwide, the prevalence of which has been increasing. Recent concept considers MMPs and TIMPs as critical factors before the onset of microalbuminuria, as well as accelerating factors associated with the breakdown of the glomerular basement membrane, renal scarring, and fibrosis during the progression of kidney diseases. Here we reviewed studies of the expression of MMPs and TIMPs in humans, using as clinical samples serum, plasma, and urine, with a focus on their potential role as molecular markers in CKD and AKI, as non-invasive markers. MATERIAL AND METHODS: We used as data sources, studies at Medline database using combinations of the following keywords: CKD, AKI, MMP, TIMP, serum, plasma, and urine. RESULTS: Evidence suggests that MMPs/TIMPs could be potential targets for therapeutic intervention in kidney diseases; future studies should attempt to improve the diagnostic or prognostic power of these families. DISCUSSION: Considering published guides, such as biospecimen reporting for improved study quality (BRISQ), strengthening the reporting of observational studies in epidemiology (STROBE), an updated list of essential items for reporting diagnostic accuracy studies (STARD), transparent reporting of a multivariate prediction model for individual prognosis or diagnosis (TRIPOD), and on the studies reviewed here, we have adapted published recommendations and proposed other news in order to enhance the transparency and quality of MMPs/TIMPs research in CKD and AKI. This review reinforces the complexities of MMPs/TIMPs in the pathobiology of the kidney and the need for well-designed and transparent biomedical studies. HIPPOKRATIA 2018, 22(3): 99-104. Copyright 2018, Hippokratio General Hospital of Thessaloniki.
INTRODUCTION: Matrix metalloproteinases (MMPs) are a family of zinc-dependent proteinases involved in remodeling the extracellular matrix. Tissue inhibitors of metalloproteinases (TIMPs) are a family of four proteins that act to limit the degradative actions of MMPs. Chronic kidney disease (CKD) and acute kidney injury (AKI) are public health problems worldwide, the prevalence of which has been increasing. Recent concept considers MMPs and TIMPs as critical factors before the onset of microalbuminuria, as well as accelerating factors associated with the breakdown of the glomerular basement membrane, renal scarring, and fibrosis during the progression of kidney diseases. Here we reviewed studies of the expression of MMPs and TIMPs in humans, using as clinical samples serum, plasma, and urine, with a focus on their potential role as molecular markers in CKD and AKI, as non-invasive markers. MATERIAL AND METHODS: We used as data sources, studies at Medline database using combinations of the following keywords: CKD, AKI, MMP, TIMP, serum, plasma, and urine. RESULTS: Evidence suggests that MMPs/TIMPs could be potential targets for therapeutic intervention in kidney diseases; future studies should attempt to improve the diagnostic or prognostic power of these families. DISCUSSION: Considering published guides, such as biospecimen reporting for improved study quality (BRISQ), strengthening the reporting of observational studies in epidemiology (STROBE), an updated list of essential items for reporting diagnostic accuracy studies (STARD), transparent reporting of a multivariate prediction model for individual prognosis or diagnosis (TRIPOD), and on the studies reviewed here, we have adapted published recommendations and proposed other news in order to enhance the transparency and quality of MMPs/TIMPs research in CKD and AKI. This review reinforces the complexities of MMPs/TIMPs in the pathobiology of the kidney and the need for well-designed and transparent biomedical studies. HIPPOKRATIA 2018, 22(3): 99-104. Copyright 2018, Hippokratio General Hospital of Thessaloniki.
Authors: Magda Elena Hernández-Hernández; Jaime Morales-Romero; Clara Luz Sampieri; Diego Jesús Luna Lozano; Isidra Del Carmen Valencia Lezama; Mónica Janett Muñoz Contreras; Arturo Rodríguez Hernández Journal: High Alt Med Biol Date: 2017-05-01 Impact factor: 1.981
Authors: Jennifer Vandooren; Nathalie Geurts; Erik Martens; Philippe E Van den Steen; Ghislain Opdenakker Journal: Nat Methods Date: 2013-03 Impact factor: 28.547
Authors: Maryam Shabihkhani; Gregory M Lucey; Bowen Wei; Sergey Mareninov; Jerry J Lou; Harry V Vinters; Elyse J Singer; Timothy F Cloughesy; William H Yong Journal: Clin Biochem Date: 2014-01-12 Impact factor: 3.281
Authors: Kathryn M Thrailkill; Robert C Bunn; Cynthia S Moreau; Gael E Cockrell; Pippa M Simpson; Hannah N Coleman; J Paul Frindik; Stephen F Kemp; John L Fowlkes Journal: Diabetes Care Date: 2007-06-11 Impact factor: 19.112
Authors: Anna Gluba-Brzózka; Marta Michalska-Kasiczak; Beata Franczyk; Marek Nocuń; Peter Toth; Maciej Banach; Jacek Rysz Journal: Lipids Health Dis Date: 2016-02-03 Impact factor: 3.876